Arrowhead Pharmaceuticals (ARWR) said Monday it dosed the first patients in a phase 1/2a clinical trial of ARO-INHBE, the company's investigational therapy to counter obesity.
The study will treat patients with ARO-INHBE as monotherapy in part 1 and in combination with tirzepatide in part 2.
The company also recently filed for regulatory clearance to launch a clinical trial of its second obesity candidate, ARO-ALK7.
Shares of the company were up more than 2.5% in Monday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。